Together, these substitutions account for approximately 11% of previously described TP53 cancer‐associated mutations. In addition, several mutations identified in this study at codons 176, 177, 244 and 270 are in close proximity to high‐frequency cancer‐associated codons. This evidence concerns the gene TP53 and cancer.